AxoGen, Inc. (NASDAQ:AXGN) is set to announce third quarter earning results on Thursday 29th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, AXGN to report 3Q20 loss of $ 0.14 per share.
For the full year, analysts anticipate top line of $ 100.89 million, while looking forward to loss of $ 0.63 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 30.00 million ~ $ 30.00 million
Full Year 2020 topline are forecasted in a range of$ 124.00 million ~ $ 128.00 million
Click Here For More Historical Outlooks Of AxoGen, Inc.
Previous Quarter Performance
AxoGen, Inc. announced loss for the second quarter of $ 0.15 per share, from the revenue of $ 22.12 million. According to street consensus, AXGN was expected to report 2Q20 loss of $ 0.38 per share from revenue of $ 13.15 million. The bottom line results beat street analysts by $ 0.23 or 60.53 percent, at the same time, top line results outshined analysts by $ 8.97 million or 68.21 percent.
Stock Performance
Shares of AxoGen, Inc. traded low $ -0.35 or -2.79 percent on Wednesday, reaching $ 12.19 with volume of 354.70 thousand shares. AxoGen, Inc. has traded high as $ 12.29 and has cracked $ 11.62 on the downward trend
According to the previous trading day, closing price of $ 12.19, representing a 75.14 % increase from the 52 week low of $ 7.16 and a 33.44 % decrease over the 52 week high of $ 18.84.
The company has a market capital of $ 488.63 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
AxoGen, Inc. will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.axogeninc.com
AxoGen, Inc. provides surgical solutions for physical damage or transection to peripheral nerves. The companys products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
